[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1988

Enalapril Therapy in Patients With Renal Function Impairment

Author Affiliations

St Michael's Hospital Annex 38 Shuter St Toronto, Ontario, Canada M5B 1A6

Arch Intern Med. 1988;148(11):2343-2344. doi:10.1001/archinte.1988.00380110009002
Abstract

The angiotensin-converting enzyme inhibitor (ACEI), enalapril maleate, is a nonsulfydryl group—containing compound. Accordingly, it is said to be less associated with side effects such as taste disturbance, rashes, proteinuria, and interstitial nephritis; these side effects having been observed with captopril, and attributed to its sulfydryl group. Enalapril is a pro-drug. Because the active compound, enalaprilic acid, is poorly absorbed, the drug is given as an absorbable ester, which is then hydrolyzed to the active compound. This results in a more gradual onset of antihypertensive effect than may be seen with captopril. However, enalapril is a more potent ACEI than captopril, and its pharmacologic half-life is prolonged, permitting once daily dosage.

See also p 2358.

The consequences of ACEI therapy are complex, multidimensional, and imperfectly understood.1 The inhibition of the enzyme that converts the inactive decapeptide angiotensin-I into the potent pressor agent angiotensin-II has systemic and intrarenal consequences. Systemically, decreased

First Page Preview View Large
First page PDF preview
First page PDF preview
×